Feller L, Chandran R, Kramer B, Khammissa RA, Altini M, Lemmer J
"A lot of doctors don't recognize it with women at all, so here you have all these women on this drug and it's making them healthier, but they're going through this too," she continued
This unexpected side effect led to further studies
GLP-1 receptor agonists confer no increased rates of IBD exacerbation among patients with IBD
Currently there are no studies confirming safe or effective use in humans either taken orally or injected
Technically, when the FDA first yanked tirzepatide off its shortage list in October 2024, both 503As and 503Bs could no longer legally make copycats (with one notable exception for the smaller 503As, who could still fill individual prescriptions if there was a medical reason the patient needed a slightly different version than the brand-name drugmore on this later)